期刊文献+

匹伐他汀联合曲美他嗪对慢性心衰患者神经内分泌因子及心功能的影响 被引量:5

Effect of Pivastatin Combined with Trimetazidine on Neuroendocrine Factor and Cardiac Function in Patients with Chronic Heart Failure
下载PDF
导出
摘要 【目的】分析匹伐他汀联合曲美他嗪对慢性心衰患者神经内分泌因子及心功能的影响。【方法】选择本院收治的136例慢性心衰患者,根据用药不同将其分为观察组(曲美他嗪+匹伐他汀,n=70)和对照组(曲美他嗪,n=66)。比较两组治疗前后心功能指标[左心室收缩末期内径(LVESD)、左心室舒张末期内径(LVEDD)以及左心室射血分数(LVEF)]、6min步行试验、血浆神经内分泌因子水平[血浆心钠素(ANP)、血浆脑钠肽(BNP)、血浆内皮素(ET)]。【结果】治疗后两组患者LVEDD、LVESD低于治疗前,LVEF高于治疗前,且组间比较差异均有统计学意义(均P<0.05)。治疗后观察组、对照组6 min步行距离均大于治疗前,且观察组大于对照组,差异有统计学意义(P<0.05)。治疗后两组患者血浆ANP、BNP、ET水平均低于治疗前,且观察组低于对照组,差异有统计学意义(P<0.05)。【结论】匹伐他汀联合曲美他嗪可有效抑制慢性心衰患者神经内分泌系统过度激活,逆转心室重塑,疗效较佳,值得临床推广应用。 【Objective】To analyze the effects of Pivastatin combined with Trimetazidine on neuroendocrine factors and cardiac function in patients with chronic heart failure.【Methods】One hundred and thirty-six patients with chronic heart failure admitted to our hospital were divided into observation group (trimetazidine + pitavastatin,n=70) and control group (trimetazidine,n=66) according to different medications.The cardiac function indexes [left ventricular end systolic diameter (LVESD),left ventricular end diastolic diameter (LVEDD) and left ventricular ejection fraction (LVEF)],6-minute walking test,plasma levels of neuroendocrine factors [plasma atrial natriuretic peptide (ANP),plasma brain natriuretic peptide (BNP),plasma endothelin (ET)] were compared between the two groups before and after treatment.【Results】After treatment,the LVEDD and LVESD of the two groups were lower than before treatment,and the LVEF was higher than before treatment,and the difference between the two groups was statistically significant (P<0.05).After treatment,the 6-minute walking distance of the observation group and the control group was greater than that before treatment,and the observation group was larger than that of the control group,the difference was statistically significant (P<0.05).After treatment,the levels of plasma ANP,BNP and ET in the two groups were lower than those before treatment,and those in the observation group were lower than those in the control group (P<0.05).【Conclusion】Pivastatin combined with trimetazidine can effectively inhibit the overactivation of neuroendocrine system and reverse ventricular remodeling in patients with chronic heart failure.It has a good effect and is worthy of clinical application.
作者 谭德胜 曹刚 徐强 梁心慧 周凤 沈颖 林琳 许宁 TAN De-sheng;CAO Gang;XU Qiang(Shaoguan Railway Hospital,Shaoguan Guangdong 512023)
出处 《医学临床研究》 CAS 2019年第8期1531-1532,1535,共3页 Journal of Clinical Research
基金 韶关市卫生计生科研项目(编号Y18178).
关键词 心力衰竭/药物疗法 曲美他嗪/药理学 羟甲基戊二酰基CoA还原酶抑制剂/药理学 Heart Failure/DT Trimetazidine/PH Hydroxymethylglutaryl-CoA Reductase Inhibitors/PH
  • 相关文献

参考文献6

二级参考文献89

  • 1托伐普坦临床研究协作组,张健,朱文玲.常规治疗基础上联用托伐普坦片治疗心原性水肿的有效性和安全性的多中心随机、双盲、安慰剂对照研究[J].中华心力衰竭和心肌病杂志(中英文),2017,1(1):15-21. 被引量:26
  • 2耿爱莲,李保明,呙于明.L-肉碱与辅酶Q_(10)添加对腹水症肉鸡心肌细胞凋亡及抗氧化能力的影响[J].中国农业大学学报,2007,12(2):21-26. 被引量:6
  • 3中华医学会心血管病分会.中华心血管病杂志编辑委员会.慢性心力衰竭诊断及治疗指南[J].中华心血管病杂志,2007,35(12):112-113.
  • 4Nakagomi A, Seino Y,Noma S, et al. Relationships betweenthe serum cholesterol levels,production of monocyte proinflam-matory cytokines and long-term prognosis in patients with chro-nic heart failure[J]. Intern Med,2014,53(21) :2415-2424.
  • 5Fedacko J,Singh RB,Gupta A, et al. Inflammatory mediatorsin chronic heart failure in North India[J]. Acta Cardiol,2014,69.4):391-398.
  • 6Egorova EN,Kalinkin MN,Mazur ES. Endotoxinemia and sys-temic inflammation in pathogenesis of chronic heart failure[J]. Patol Fiziol Eksp Ter,2011, (4) : 42-46.
  • 7Oyama J, Kudo Y,Maeda T,et al. Hyperthermia by bathing ina hot spring improves cardiovascular functions and reduces theproduction of inflammatory cytokines in patients with chronicheart failure[J]. Heart Vessels,2013,28(2) : 173-178.
  • 8Ozova EM, Kiiakbaev GK, Kobalava ZhD,et al. Effect ofcarvedilol and metoprolol R administered with or without ator-vastatin on elastic properties of vascular wall and parametersof inflammation in patients with chronic heart failure of ische-mic origin. [J]. Kardiologiia, 2011,51(4) :39-46.
  • 9Feola M, Lombardo E, Taglieri C,et al. Plasma BNP and renalfailure as prognostic factors of mid-term clinical outcome incongestiveheart failure patients [J]. Int J Cardiol,2011,149(1): 114-115.
  • 10Jensen J. Ma LP,Bjurman C.et al. Prognostic values of NTproBNP/BNP ratio in comparison with NTpro BNP or BNP alonein elderly patients with chronic heart failure in a 2-year followup[J]. Int J Cardiol,2012,155(1) :l-5.

共引文献5925

同被引文献61

引证文献5

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部